Advocacy Webpage Graphics Teach It
TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma
Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of individualized addiction treatment so that more patients receive high-quality, evidence-based care
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to comprehensive, high-quality addiction care

Leading the movement to transform America's addiction treatment infrastructure and expand access to research-validated, results-based care

 

ASAM Policy Principles

ASAM believes in a future in which addiction prevention, treatment, remission, and recovery are accessible to all, and where they profoundly improve the health of all people. The following principles guide our advocacy and shape ASAM's advocacy priorities:
  • Addiction policy should be guided by - and promote the use of - the latest science and best practices in addiction prevention, treatment, remission, and recovery.  People with addiction deserve compassionate, evidence-based care that addresses the chronic nature of the disease of addiction.
  • Strategic and multifaceted policy solutions are needed to drive the development of a more accessible, effective, robust, and comprehensive addiction prevention and treatment infrastructure.
  • Policies and payment systems should ensure equitable access to comprehensive, high-quality addiction prevention, treatment, and recovery services.
  • Policy should challenge, rather than enforce, cultural misunderstanding, stigma and discrimination about the disease of addiction.
  • Addiction policy and advocacy should respect and integrate the perspectives of people with addiction and their families.
newspapers-3488857_1920B

ASAM Endorses the Cannabidiol and Marijuana Research Expansion Act

by | Jul 01, 2019

 

On June 27, Senator Dianne Feinstein (D-CA), Senator Chuck Grassley (R-IA), and Senator Brian Schatz (D-HI) introduced the Cannabidiol and Marijuana Research Expansion Act, which would reduce barriers to the study of cannabis and its compounds, including cannabidiol (CBD), for use in the treatment of medical conditions. ASAM endorsed the bill in a letter from the Friends of the National Institute on Drug Abuse in May. There is a significant lack of research and understanding surrounding the effects of cannabis derived substances on both adolescents and adults. As an organization committed to advocating for the use of evidence-based treatment, ASAM is excited for the increased research into cannabis related substances that this bill would encourage. 

 

The bill improves interagency efficiency by requiring that the Department of Justice (DoJ) approve applications for Schedule I registration if the researchers’ protocols have been reviewed and approved by other federal science agencies, and adequate security measures exist to prevent abuse and diversion. The bill additionally requires that the process for approving applications for Schedule I registration, as well as the process for approving requests to increase the quantity of a substance being used for an approved research protocol, be expedited. Furthermore, the bill would authorize medical and osteopathic schools, research universities, and pharmaceutical companies to manufacture their own cannabis to conduct research. All of these provisions would greatly improve the medical communities ability to understand the potential treatment benefits, as well as harms, related to cannabis derived substances.

 

Read the bill text here.

 

Read the Friends of NIDA letter here.